In Vivo topoisomerase i inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis

Molecular Medicine

Volumn 18, Issue 1, 2012, Pages 83-94

  Guérin, Eric ^a,b   Raffelsberger, Wolfgang ^c   Pencreach, Erwan ^a,b   Maier, Armin ^d   Neuville, Agnès ^b   Schneider, Anne ^a,b   Bachellier, Philippe ^b   Rohr, Serge ^b   Petitprez, Amélie ^e,f,g   Poch, Olivier ^c   Moras, Dino ^c   Oudet, Pierre ^b   Larsen, Annette K ^e,f,g   Gaub, Marie Pierre ^a,b   Guenot, Dominique ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

^c INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^d CHARLES RIVER LABORATORIES   (United States)

^e CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^f INSERM   (France)

^g SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; DNA TOPOISOMERASE; FLUOROURACIL; FOLINIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CANCER CONTROL; CANCER SIZE; CLINICAL ARTICLE; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION;

EID: 84857022444     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00120     Document Type: Article

References (54)

1. Guenot D, et al. (2006) Primary tumour genetic alterations and intra-tumoral heterogeneity are maintained in xenografts of human colon cancers showing chromosome instability. J. Pathol. 208:643-52.
2. Saltz LB, et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan study group. N. Engl. J. Med. 343:905-14.
3. Douillard JY, et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colo-rectal cancer: a multicentre randomised trial. Lancet. 355:1041-7.
4. Cunningham D, et al. (2004) Cetuximab monother-apy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351:337-45.
5. Hurwitz H, et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350:2335-42.
6. Van Cutsem E, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colo-rectal cancer. N. Engl. J. Med. 360:1408-17.
7. Champoux JJ. (2001) DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem. 70:369-413.
8. Liu LF, et al. (2000) Mechanism of action of camp-tothecin. Ann. N. Y. Acad. Sci. 922:1-10.
9. Bhonde MR, et al. (2006) Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Oncogene. 25:165-75.
10. Pommier Y. (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer. 6:789-802.
11. Naef F, Huelsken J. (2005) Cell-type-specific tran-scriptomics in chimeric models using transcrip-tome-based masks. Nucleic Acids Res. 33:e111.
12. Fiebig HH, Maier A, Burger AM. (2004) Clono-genic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur. J. Cancer. 40:802-20.
13. Raffelsberger W, et al. (2008) RReportGenerator: automatic reports from routine statistical analysis using R. Bioinformatics. 24:276-8.
14. Bolstad BM, Irizarry RA, Astrand M, Speed TP. (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 19:185-93.
15. Irizarry RA, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31:e15.
16. Gentleman RC, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5:R80.
17. Reiner A, Yekutieli D, Benjamini Y. (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinfor-matics. 19:368-75.
18. Strimmer K. (2008) Fdrtool: a versatile R package for estimating local and tail area-based false discovery rates. Bioinformatics. 24:1461-2.
19. Dennis G, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4:P3.
20. Suzuki R, Shimodaira H. (2006) Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics. 22:1540-2.
21. Pencreach E, et al. (2009) Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin. Cancer Res. 15:1297-307.
22. Prewett MC, et al. (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorec-tal tumor xenografts. Clin. Cancer Res. 8:994-1003.
23. Denko NC, et al. (2003) Investigating hypoxic tumor physiology through gene expression patterns. Oncogene. 22:5907-14.
24. Semenza GL. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 3:721-32.
25. Semenza GL. (2010) Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 29:625-34.
26. Pouysségur J, Dayan F, Mazure NM. (2006) Hy-poxia signalling in cancer and approaches to enforce tumour regression. Nature. 441:437-43.
27. Gordan JD, Simon MC. (2007) Hypoxia-inducible factors: central regulators of the tumor pheno-type. Curr. Opin. Genet. Dev. 17:71-7.
28. Rankin EB, Giaccia AJ. (2008) The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 15:678-85.
29. Zhong H, et al. (1999) Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res. 59:5830-5.
30. Su AI, et al. (2004) A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. U. S. A. 101:6062-7.
31. Simiantonaki N, Taxeidis M, Jayasinghe C, Kurzik-Dumke U, Kirkpatrick CJ. (2008) Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression. BMC Cancer. 8:320.
32. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7:11-20.
33. Semenza GL. (2009) Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin. Cancer Biol. 19:12-6.
34. May D, et al. (2005) Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hy-poxia: implication for cancer. Oncogene. 24:1011-20.
35. Nikitenko LL, Fox SB, Kehoe S, Rees MC, Bick-nell R. (2006) Adrenomedullin and tumour an-giogenesis. Br. J. Cancer. 94:1-7.
36. Schreiber V, Dantzer F, Ame JC, de Murcia G. (2006) Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell. Biol. 7:517-28.
37. Kleine H, et al. (2008) Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribo-sylation. Mol. Cell. 32:57-69.
38. Zhou Y, et al. (2002) Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res. 62:1688-95.
39. Daoud SS, et al. (2003) Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharma-cogenomic study. Cancer Res. 63:2782-93.
40. Minderman H, et al. (2005) In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol. Cancer Ther. 4:885-900.
41. Souza V, Dong YB, Zhou HS, Zacharias W, Mc-Masters KM. (2005) SW-620 cells treated with topoisomerase I inhibitor SN-38: gene expression profiling. J. Transl. Med. 3:44.
42. Bhonde MR, et al. (2006). DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis. J. Biol. Chem. 281:8675-85.
43. Guo X, et al. (2006) Analysis of common gene expression patterns in four human tumor cell lines exposed to camptothecin using cDNA microar-ray: identification of topoisomerase-mediated DNA damage response pathways. Front. Biosci. 11:1924-31.
44. Nakashio A, Fujita N, Tsuruo T. (2002) Topotecan inhibits VEGF- and bFGF-induced vascular en-dothelial cell migration via downregulation of the PI3K-Akt signaling pathway. Int. J. Cancer. 98:36-41.
45. Petrangolini G, et al. (2003) Antiangiogenic effects of the novel camptothecin ST1481 (gimate-can) in human tumor xenografts. Mol. Cancer Res. 1:863-70.
46. Kamiyama H, Takano S, Tsuboi K, Matsumura A. (2005) Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J. Cancer Res. Clin. Oncol. 131:205-13.
47. Ji Y, et al. (2007) The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color im-ageable orthotopic metastatic nude mouse model of human colon cancer. Anticancer Res. 27:713-8.
48. Bocci G, et al. (2008) Antiangiogenic and anticol-orectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with se-maxinib. Br. J. Cancer. 98:1619-29.
49. Takano S, et al. (2010) Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth. J. Neurooncol. 99:177-85.
50. Pastorino F, et al. (2010) Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoiso-merase I inhibitor. Clin. Cancer Res. 16:4809-21.
51. Sapra P, et al. (2011) Potent and sustained inhibition of HIF-1α and downstream genes by a poly-ethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects. Angiogenesis. 14:245-53.
52. Rapisarda A, et al. (2002) Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. Cancer Res. 62:4316-24.
53. Rapisarda A, et al. (2004) Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res. 64:6845-8.
54. Rapisarda A, et al. (2004) Topoisomerase I-medi-ated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res. 64:1475-82.